Teva Advances Schizophrenia Therapy in Europe
TEL AVIV, Israel & PARIS, May 21, 2026 Teva Pharmaceuticals and Medincell have announced that the European Medicines Agency...
Schizophrenia Treatment
Advertisement
Johnson & Johnson Strengthens CNS Portfolio with CAPLYTA FDA Nod
TITUSVILLE, NEW JERSEY, April 27, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for...
Lupin Debuts CGT-Exclusive Risperidone LAI in U.S. Market
Dateline: November 14, 2025 — Mumbai, India / Baltimore, MarylandLupin has launched its Risperidone Long-Acting Injectable (LAI) in the...
Lupin Wins U.S. FDA Approval for First Nanomi LAI Injectable
September 3, 2025 – Mumbai & Naples – Lupin Limited announced U.S. FDA approval for its Risperidone extended-release injectable...
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its risperidone...
Advertisement
